Notably, NB cells with anaplastic lymphoma kinase (ALK) mutations frequently depend on this pathway for growth and tend to exhibit considerable resistance to therapies targeting various mechanisms, highlighting the clinical challenges associated with this signaling network [53]. Here, ALK is linked to neuroblastoma.